UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response...

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type I	Responses	s)										1				
Name and Address of Reporting Person* DeVinney Erick Wayne					2. Issuer Name and Ticker or Trading Symbol Axogen, Inc. [AXGN]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) 13631 PROGRESS BOULEVARD SUITE 400					3. Date of Earliest Transaction (Month/Day/Year) 02/15/2022						X Officer (give title below) Other (specify below) VP Peripheral Nerve Science					
(Street) ALACHUA, FL 32615			4. If	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	,	(State)	(Zip)		T	able I -	- Non-	-Deri	vative S	Securities	s Acqu	ired, Disp	osed of, or l	Beneficially (Owned	
(Instr. 3) Date		2. Transaction Date (Month/Day/Year	Exec any	Deemed cution Date, i	(Instr. 8)		etion	(A) or (D)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Fol Reported Transaction(s) (Instr. 3 and 4)		ollowing Or Fo	Ownership Form: Direct (D)	Beneficial Ownership	
					Co	ode	V	Amour	(A) or (D)	Price				or Indirect (I) (Instr. 4)	(Instr. 4)	
Common St	tock		02/15/2022			1	A		1,181 (1)	A	\$ 0	88,432	<u>2)</u>		D	
Common Stock		02/15/2022]	F		357	<u>B</u> D	\$ 8.42	88,075	88,075		D		
Reminder: Rep	port on a s	eparate line fo		Deriva	ative Securit	ies Acc	F c t	Personta conta he fo	ons whained in	no respo n this fo splays a	rm are curre reficia	e not requently valid		formation spond unlea trol number	ss	1474 (9-02)
1. Title of 2. Derivative Co			3A. Deemed Execution De		4. e, if Transaction		er	6. Date Exercisable and Expiration Date		7. T Am	Citle and ount of	Derivative	9. Number of Derivative	Owners	11. Natur	
(Instr. 3) Pri De	Exercise ice of erivative ecurity	(Month/Day/\)		Year)			ative ities red	,		Sec	derlying urities str. 3 and	Security (Instr. 5)	Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Security Direct (or Indire	Ownersh (Instr. 4)	
					Code V	(A)		Date Exerc	cisable	Expiratio Date	n Titl	Amount or e Number of Shares				
Reporti	ng O	wners														

	Relationships						
Reporting Owner Name / Address		10% Owner	Officer	Other			
DeVinney Erick Wayne 13631 PROGRESS BOULEVARD SUITE 400 ALACHUA, FL 32615			VP Peripheral Nerve Science				

Signatures

/s/Erick DeVinney	02/17/2022
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This reflects the number of shares that became vested as of February 15, 2022 upon the attainment of certain performance criteria.
- (2) Includes 2 shares acquired under the Axogen stock purchase plan on December 31, 2021.
- (3) The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 15, 2022.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.